Trials / Withdrawn
WithdrawnNCT03680976
Anti-Inflammatory Lipid Mediators in Asthma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sally E. Wenzel MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics. The study's hypothesis is that 150 mg/day of CXA-10 for 12 weeks will alleviate obesity-related airway hyper-reactivity in obese adult asthmatics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CXA-10 | Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil. |
| DRUG | Placebo | Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule |
Timeline
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
- First posted
- 2018-09-21
- Last updated
- 2018-09-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03680976. Inclusion in this directory is not an endorsement.